Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

Anthony V. D'Amico, Richard Whittington, S. Bruce Malkowicz, Julie Fondurulia, Ming Hui Chen, Irving Kaplan, Clair J. Beard, John E. Tomaszewski, Andrew A. Renshaw, Alan Wein, C. Norman Coleman

Research output: Contribution to journalArticle

Abstract

Purpose: To present nomograms providing estimates of prostate-specific antigen (PSA) failure-free survival after radical prostatectomy (RP) or external-beam radiation therapy (RT) for men diagnosed during the PSA era with clinically localized disease. Patients and Methods: A Cox regression multivariable analysis was used to determine the prognostic significance of the pretreatment PSA level, 1992 American Joint Committee on Cancer (AJCC) clinical stage, and biopsy Gleason score in predicting the time to posttherapy PSA failure in 1,654 men with Tlc,2 prostate cancer managed with either RP or RT. Results: Pretherapy PSA, AJCC clinical stage, and biopsy Gleason score were independent predictors (P <.0001) of time to posttherapy PSA failure in patients managed with either RP or RT. Two-year PSA failure rates derived from the Cox regression model and bootstrap estimates of the 95% confidence intervals are presented in the format of a nomogram stratified by the pretreatment PSA, AJCC clinical stage, biopsy Gleason score, and local treatment modality. Conclusion: Men at high risk (> 50%) for early (≤ 2 years) PSA failure could be identified on the basis of the type of local therapy received and the clinical information obtained as part of the routine work-up for localized prostate cancer. Selection of these men for trials evaluating adjuvant systemic and improved local therapies may be justified.

Original languageEnglish (US)
Pages (from-to)168-172
Number of pages5
JournalJournal of Clinical Oncology
Volume17
Issue number1
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Nomograms
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Recurrence
Neoplasm Grading
Biopsy
Neoplasms
Regression Analysis
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

D'Amico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M. H., Kaplan, I., ... Coleman, C. N. (1999). Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. Journal of Clinical Oncology, 17(1), 168-172.

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. / D'Amico, Anthony V.; Whittington, Richard; Malkowicz, S. Bruce; Fondurulia, Julie; Chen, Ming Hui; Kaplan, Irving; Beard, Clair J.; Tomaszewski, John E.; Renshaw, Andrew A.; Wein, Alan; Coleman, C. Norman.

In: Journal of Clinical Oncology, Vol. 17, No. 1, 01.1999, p. 168-172.

Research output: Contribution to journalArticle

D'Amico, AV, Whittington, R, Malkowicz, SB, Fondurulia, J, Chen, MH, Kaplan, I, Beard, CJ, Tomaszewski, JE, Renshaw, AA, Wein, A & Coleman, CN 1999, 'Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer', Journal of Clinical Oncology, vol. 17, no. 1, pp. 168-172.
D'Amico, Anthony V. ; Whittington, Richard ; Malkowicz, S. Bruce ; Fondurulia, Julie ; Chen, Ming Hui ; Kaplan, Irving ; Beard, Clair J. ; Tomaszewski, John E. ; Renshaw, Andrew A. ; Wein, Alan ; Coleman, C. Norman. / Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 1. pp. 168-172.
@article{67b5db0de7644b29b34735ab2bd3fb16,
title = "Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer",
abstract = "Purpose: To present nomograms providing estimates of prostate-specific antigen (PSA) failure-free survival after radical prostatectomy (RP) or external-beam radiation therapy (RT) for men diagnosed during the PSA era with clinically localized disease. Patients and Methods: A Cox regression multivariable analysis was used to determine the prognostic significance of the pretreatment PSA level, 1992 American Joint Committee on Cancer (AJCC) clinical stage, and biopsy Gleason score in predicting the time to posttherapy PSA failure in 1,654 men with Tlc,2 prostate cancer managed with either RP or RT. Results: Pretherapy PSA, AJCC clinical stage, and biopsy Gleason score were independent predictors (P <.0001) of time to posttherapy PSA failure in patients managed with either RP or RT. Two-year PSA failure rates derived from the Cox regression model and bootstrap estimates of the 95{\%} confidence intervals are presented in the format of a nomogram stratified by the pretreatment PSA, AJCC clinical stage, biopsy Gleason score, and local treatment modality. Conclusion: Men at high risk (> 50{\%}) for early (≤ 2 years) PSA failure could be identified on the basis of the type of local therapy received and the clinical information obtained as part of the routine work-up for localized prostate cancer. Selection of these men for trials evaluating adjuvant systemic and improved local therapies may be justified.",
author = "D'Amico, {Anthony V.} and Richard Whittington and Malkowicz, {S. Bruce} and Julie Fondurulia and Chen, {Ming Hui} and Irving Kaplan and Beard, {Clair J.} and Tomaszewski, {John E.} and Renshaw, {Andrew A.} and Alan Wein and Coleman, {C. Norman}",
year = "1999",
month = "1",
language = "English (US)",
volume = "17",
pages = "168--172",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

AU - D'Amico, Anthony V.

AU - Whittington, Richard

AU - Malkowicz, S. Bruce

AU - Fondurulia, Julie

AU - Chen, Ming Hui

AU - Kaplan, Irving

AU - Beard, Clair J.

AU - Tomaszewski, John E.

AU - Renshaw, Andrew A.

AU - Wein, Alan

AU - Coleman, C. Norman

PY - 1999/1

Y1 - 1999/1

N2 - Purpose: To present nomograms providing estimates of prostate-specific antigen (PSA) failure-free survival after radical prostatectomy (RP) or external-beam radiation therapy (RT) for men diagnosed during the PSA era with clinically localized disease. Patients and Methods: A Cox regression multivariable analysis was used to determine the prognostic significance of the pretreatment PSA level, 1992 American Joint Committee on Cancer (AJCC) clinical stage, and biopsy Gleason score in predicting the time to posttherapy PSA failure in 1,654 men with Tlc,2 prostate cancer managed with either RP or RT. Results: Pretherapy PSA, AJCC clinical stage, and biopsy Gleason score were independent predictors (P <.0001) of time to posttherapy PSA failure in patients managed with either RP or RT. Two-year PSA failure rates derived from the Cox regression model and bootstrap estimates of the 95% confidence intervals are presented in the format of a nomogram stratified by the pretreatment PSA, AJCC clinical stage, biopsy Gleason score, and local treatment modality. Conclusion: Men at high risk (> 50%) for early (≤ 2 years) PSA failure could be identified on the basis of the type of local therapy received and the clinical information obtained as part of the routine work-up for localized prostate cancer. Selection of these men for trials evaluating adjuvant systemic and improved local therapies may be justified.

AB - Purpose: To present nomograms providing estimates of prostate-specific antigen (PSA) failure-free survival after radical prostatectomy (RP) or external-beam radiation therapy (RT) for men diagnosed during the PSA era with clinically localized disease. Patients and Methods: A Cox regression multivariable analysis was used to determine the prognostic significance of the pretreatment PSA level, 1992 American Joint Committee on Cancer (AJCC) clinical stage, and biopsy Gleason score in predicting the time to posttherapy PSA failure in 1,654 men with Tlc,2 prostate cancer managed with either RP or RT. Results: Pretherapy PSA, AJCC clinical stage, and biopsy Gleason score were independent predictors (P <.0001) of time to posttherapy PSA failure in patients managed with either RP or RT. Two-year PSA failure rates derived from the Cox regression model and bootstrap estimates of the 95% confidence intervals are presented in the format of a nomogram stratified by the pretreatment PSA, AJCC clinical stage, biopsy Gleason score, and local treatment modality. Conclusion: Men at high risk (> 50%) for early (≤ 2 years) PSA failure could be identified on the basis of the type of local therapy received and the clinical information obtained as part of the routine work-up for localized prostate cancer. Selection of these men for trials evaluating adjuvant systemic and improved local therapies may be justified.

UR - http://www.scopus.com/inward/record.url?scp=0032951318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032951318&partnerID=8YFLogxK

M3 - Article

C2 - 10458230

AN - SCOPUS:0032951318

VL - 17

SP - 168

EP - 172

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -